EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Aetiology‐Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO‐PEI Registry

J Enrique Domínguez-Muñoz iD, Yessica Domínguez-Novoa, Xurxo Martínez-Seara, Peter Hegyi iD, Vinciane Rebours iD, Mary E Phillips iD, Federico Bolado iD, Gabriele Capurso iD, Giulia de Marchi iD, Keith J Roberts, Orsolya Eperjesi, Sandra Salmeron iD und 6 weitere

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70282 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von J Enrique Domínguez-Muñoz und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain. Hauptthemen laut MEDLINE: Exocrine Pancreatic Insufficiency, Enzyme Replacement Therapy. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Viatris.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic exocrine insufficiency (PEI) is a maldigestion syndrome leading to symptoms and nutritional deficiencies. Prospective real‐world data on pancreatic enzyme replacement therapy (PERT) dose requirements across aetiologies are limited.

Objective

To define PERT dose requirements and treatment outcomes across PEI aetiologies in specialist European practice.

Methods

EURO‐PEI was a multicentre observational registry with predominantly prospective data collection conducted at eight pancreatic centres in five European countries between June 2021 and September 2025. Adults with clinician‐established PEI in whom PERT was initiated or actively optimised were included. The primary outcome was the optimised PERT dose associated with the achievement of a clinician‐assessed therapeutic goal: improvement or resolution of PEI‐related symptoms with normalisation or clinically relevant improvement of nutritional abnormalities.

Results

Among 1015 patients, PEI was secondary to chronic pancreatitis in 496 (48.9%), pancreatectomy in 185 (18.2%), pancreatic cancer in 174 (17.1%), and acute pancreatitis in 95 (9.4%). Median total daily optimised doses were highest after pancreatectomy (240,000 PhU, IQR 175,000–375,000) and in pancreatic cancer (210,000 PhU, 175,000–325,000), compared with chronic pancreatitis (175,000 PhU, 120,000–210,000) and acute pancreatitis (100,000 PhU, 75,000–200,000). After optimisation, the therapeutic goal was achieved in 951 patients (93.7%); of these, 446 (46.9%) required enzyme doses exceeding commonly recommended starting doses. Related adverse events occurred in 38 patients (3.7%).

Conclusions

PERT dose requirements vary substantially by PEI aetiology, supporting aetiology‐aware starting doses, early reassessment, and individualised optimisation in high‐risk groups.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Exocrine Pancreatic InsufficiencyEnzyme Replacement TherapyHumansRegistriesFemaleMaleMiddle AgedTreatment OutcomePancreatectomyEuropeAgedPancreatitis, ChronicProspective StudiesAdultPancreatic NeoplasmsDose-Response Relationship, Drug

Stichwörter der Autor:innen

chronic pancreatitisdose optimisationpancreatectomypancreatic cancerpancreatic enzyme replacement therapypancreatic exocrine insufficiencyreal‐world evidence

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.
  • Health Research Institute (IDIS) of Santiago de Compostela, Santiago de Compostela, Spain.
  • Institute of Pancreatic Diseases, Semmelweis University, Budapest, Hungary.
  • Centre for Translational Medicine, Semmelweis University, Budapest, Hungary.
  • Institute for Translational Medicine, Medical School, University of Pécs, Pécs, Hungary.
  • Translational Pancreatology Research Group, Interdisciplinary Centre of Excellence for Research Development and Innovation, University of Szeged, Szeged, Hungary.

ORCID-Profile: J Enrique Domínguez-Muñoz, Peter Hegyi, Vinciane Rebours, Mary E Phillips, Federico Bolado, Gabriele Capurso, Giulia de Marchi, Sandra Salmeron, Gaetano Lauri, Alessandro Brillo, Julio Iglesias-García

Förderung

  • Viatris

Zitieren

APA

Domínguez-Muñoz, J. E., Domínguez-Novoa, Y., Martínez-Seara, X., Hegyi, P., Rebours, V., Phillips, M. E., Bolado, F., Capurso, G., de Marchi, G., Roberts, K. J., Eperjesi, O., Salmeron, S., Ruiz-Clavijo, D., Lauri, G., Brillo, A., Powell-Brett, S., Lariño-Noia, J., & Iglesias-García, J. (2026). Aetiology‐Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO‐PEI Registry. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70282

Vancouver

Domínguez-Muñoz JE, Domínguez-Novoa Y, Martínez-Seara X, Hegyi P, Rebours V, Phillips ME, et al. Aetiology‐Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO‐PEI Registry. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70282

BibTeX
@article{DomnguezMuoz2026,
  author = {Domínguez-Muñoz, J Enrique and Domínguez-Novoa, Yessica and Martínez-Seara, Xurxo and Hegyi, Peter and Rebours, Vinciane and Phillips, Mary E and Bolado, Federico and Capurso, Gabriele and de Marchi, Giulia and Roberts, Keith J and Eperjesi, Orsolya and Salmeron, Sandra and Ruiz-Clavijo, David and Lauri, Gaetano and Brillo, Alessandro and Powell-Brett, Sarah and Lariño-Noia, Jose and Iglesias-García, Julio},
  title = {Aetiology‐Specific Pancreatic Enzyme Dose Requirements and Treatment Outcomes in Pancreatic Exocrine Insufficiency: The Multicentre EURO‐PEI Registry},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70282}
}
Kostenlos starten →